A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.


Updates from The Motley Fool

Latest updates on Orexigen Therapeutics from Fool.com.  The Fool has written over 200 articles on Orexigen Therapeutics.
The Worst Biotech Stocks in 2015

Image Source: Wikimedia Commons Disastrous. That's the best description for the performance of a...

Obesity Drugs: Stocks to Watch

Obesity is a big healthcare problem. In the U.S. alone, an estimated 35% of adults, or 85 million...



Stock Performance

View Interactive OREX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Orexigen Therapeutics.
Current Price: $1.90
Prev Close: $1.90
Open: $1.88
Bid: $1.82
Ask: $2.00
Day's Range: $1.88 - $1.99
52wk Range: $1.75 - $21.61
Volume: 119,820
Avg Vol 133,835
Market Cap: $276M
P/E (ttm): -1.64
EPS (ttm): ($1.16)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Orexigen Therapeutics.
CAPS Rating 1 out of 5
 
209 Outperform
60 Underperform
CAPS All Stars
 
35 Outperform
14 Underperform

How do you think Orexigen Therapeutics will perform against the market?



You pick for Orexigen Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Michael A. Narachi, CEO

100% Approve

Based on 2 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Orexigen Therapeutics.

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers